2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1787 Prognostic impact of POD24 across different treatment strategies in Waldenström macroglobulinemia treated with bendamustine-rituximab, dexamethasone-rituximab-cyclophosphamide and BTK inhibitors.

Francesco Autore, MD, Annamaria Frustaci, MD2, Giulia Benevolo, MD3, Nicolò Danesin, MD4, Diana Giannarelli5, Rita Rizzi6, Maura Nicolosi, MD7, Emanuele Cencini8, Raffaella Pasquale9, Concetta Conticello, MD10, Sara Steffanoni11, Martina Bullo12, Dario Marino, MD, PhD13, Massimo Gentile14, Idanna Innocenti, MD, PhD15, Luca Stirparo16, Francesco Piazza, MD17, Giorgia D'Uva18, Alessandra Tedeschi19, Luca Laurenti Sr, MD20
1 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
2 Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
3 Ematologia Universitaria A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
4 Hematology Unit, Department of Medicine, University of Padova, Padova, Italy, Pdova, Italy
5 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
6 Università degli Studi 'Aldo Moro,' A.O.U. Consorziale Policlinico di Bari, Bari, Italy
7 SC Ematologia, AOU Città della Salute e della Scienza,, Torino, Italy
8 A.O.U. Senese e Università di Siena,, Siena, Italy
9 Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
10 Divisione di Ematologia e Trapianto di Midollo Osseo, Policlinico Gaspare Rodolico di Catania, Catania, Italy
11 Centro Valduce di Como, Como, Italy
12 Ordine Mauriziano di Torino, Torino, Italy
13 Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
14 Azienda Ospedaliera di Cosenza, Cosenza, Italy
15 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
16 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
17 Hematology Unit, Department of Medicine, University of Padova, Padova, Italy, Pdova, Italy
18 Ematologia Universitaria A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
19 Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
20 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy

Progression of disease within 24 months (POD24) is a validated dynamic prognostic marker in patients with follicular lymphoma receiving frontline immunochemotherapy, whereas its prognostic role in Waldenström Macroglobulinemia (WM) across different treatment settings, including relapsed disease, remains poorly defined.

Our aim was to evaluate the prognostic impact of POD24 in WM and to compare its discriminatory value with IPSSWM and mutational status.

We conducted a multicenter retrospective FIL study including WM patients treated with frontline bendamustine-rituximab (BR, n=244), frontline dexamethasone-rituximab-cyclophosphamide (DRC, n=116), and BTK inhibitors (BTKi) in relapsed disease (n=102: 71 ibrutinib, 31 zanubrutinib). Survival was estimated by Kaplan–Meier and compared by log-rank test. The impact of POD24 on survival outcomes has been evaluated through a landmark analysis considering a 24-months mark.  Standardized mortality ratios (SMR) were calculated using matched general population data. Median follow-up was 54, 59, and 44 months for BR, DRC, and BTKi, respectively.

POD24 incidence was 9.4% in the BR cohort, 25.8% in DRC and 16.9% in BTKi. Across all cohorts, POD24 was associated with significantly inferior overall survival (OS) respect to non-POD24: BR (5-year OS 57% vs 83%, HR 4.6 (95% CI: 1.9-11.0), p<0.001), DRC (64% vs 84%, HR 3.1 (95% CI: 1.2-8.4), p=0.016), and BTKi (0% vs 79%, HR 15.7 (95% CI: 5.0-49.6), p<0.001). In the BR cohort, POD24 patients showed increased mortality compared with the general population (SMR 4.8), whereas non-POD24 patients had only a modest excess risk (SMR 2.3). In the DRC cohort, SMR was 5.1 for POD24 versus 1.9 for non-POD24. The most pronounced difference was observed in the BTKi cohort, where POD24 patients had extremely high mortality (SMR 22.2), while non-POD24 patients showed a limited increase (SMR 3.5).

CXCR4 mutations were associated with inferior outcomes, particularly in BTKi-treated patients, whereas MYD88L265P status did not significantly impact OS. Among BTKi patients in the landmark analysis, 13 experienced POD24: 10 treated with ibrutinib and 3 with zanubrutinib. MYD88 was wild-type in 23%, mutated in 61%, and unknown in 15%; CXCR4 was wild-type in 15%, mutated in 23%, and unknown in 61%.  Prior therapies included BR (31%), DRC (61%), and other R-chemotherapies (8%).

Considering basal clinical characteristics, a solely correlation between age and POD24 was found in BR cohort (OR 1.08; 95% CI: 1.02-1.14; p=0.009). No correlation was observed between POD24 and high IPSSWM (p=0.18). POD24 appeared to provide stronger prognostic discrimination than IPSSWM in BR-treated patients, whereas IPSSWM retained greater prognostic value in DRC cohort.

In conclusion, POD24 could potentially represent a prognostic marker for WM across distinct treatment settings including relapsed disease treated with BTK inhibitors, given its impact on survival outcomes and as compared to the outcomes of the general population. Main limitations are the retrospective design of the study in addition to the missing data regarding mutational status and the small number of second progressions in the BTKi cohort. These findings might suggest the incorporation of POD24 into risk-adapted strategies and its potential use as early surrogate endpoint in prospective clinical trials.

Francesco Autore, MD: No relevant conflicts of interest to declare.